Acute Myocardial Infarction (AMI)NCT07705997
Prospective Cohort Study of Aging in Patients With Acute Myocardial Infarction
An observational study of Acute Myocardial Infarction (AMI), run by The Affiliated Hospital of Hangzhou Normal University at 1 site in China.
Trial summary
This is a single-center, prospective, observational cohort study designed to investigate the association between aging-related characteristics and long-term outcomes in patients with acute myocardial infarction (AMI). Read more about this study
- Who is it for?
- Ages 60 years and older
- Conditions the study is for
- Acute Myocardial Infarction (AMI)
- How many people
- 600 participants
- Where
- 1 siteChina
- Study dates
- 1 Aug 2026to 1 Sep 2030
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 60 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The study population includes consecutively enrolled patients with acute myocardial infarction (AMI) and aging characteristics at a single center. Eligible participants will undergo standardized clinical assessment, aging evaluation, biospecimen collection, and prospective follow-up to investigate aging-related biomarkers and long-term clinical outcomes.
Who may be able to join
- 1. Age ≥ 60 years old and meet the above comprehensive aging assessment criteria (i.e., combined with at least one clinical phenotype of aging and abnormal blood aging markers on the basis of advanced age); 2. Acute myocardial infarction occurs for ≥ 3 months; 3. Meet the diagnostic criteria for AMI in accordance with the Fourth Edition General Definition of Myocardial Infarction; 4. The patient or their legal representative signs an informed consent form.
Who cannot join
- 1. Newly diagnosed acute myocardial infarction, angina pectoris, stroke or transient ischemic attack within the past 3 months; 2. Serious life-threatening diseases (such as advanced malignant tumors, end-stage kidney disease/liver disease, severe infections) with an estimated lifespan of less than 1 year; 3. Severe cognitive impairment, mental illness, inability to cooperate in completing follow-up, aging assessment, and related examinations; 4. Unable to complete assessment items such as grip strength, walking speed, and 6-minute walk test due to non cardiac reasons such as physical disabilities and severe bone and joint diseases; 5. Failed to sign the informed consent form.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site
MingWei Wang
Hanzhou, Zhejiang, 310000
MingWei W Wang, PhD, 86-18758871517 ext. NOT, wmw990556@163.com
About this study
Official title: A Single-Center, Prospective, Observational Registry Cohort Study to Investigate Aging-Related Biomarkers, Prognosis, and Risk Prediction in Patients With Acute Myocardial Infarction
This is a single-center, prospective, observational cohort study designed to investigate the association between aging-related characteristics and long-term outcomes in patients with acute myocardial infarction (AMI). Approximately 588 eligible participants will be consecutively enrolled and followed for at least 24 months. Clinical data, aging assessments, laboratory examinations, cardiac imaging, and blood samples will be collected to establish a clinical database and biobank. The study aims to identify aging-related prognostic biomarkers, develop a risk prediction model integrating clinical and aging-related indicators, and improve risk stratification and individualized management for patients with AMI.
- Conditions
- Acute Myocardial Infarction (AMI)
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Patients With Acute Myocardial Infarction and Aging Characteristics | Patients with acute myocardial infarction (AMI) and aging characteristics who meet the eligibility criteria will be consecutively enrolled in this prospective observational cohort. Participants will undergo comprehensive clinical evaluation, aging assessment, laboratory testing, cardiac imaging, biospecimen collection, and standardized follow-up for at least 24 months to investigate aging-related biomarkers, clinical outcomes, and prognostic risk prediction. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Major adverse cardiovascular events (MACE)
The occurrence of major adverse cardiovascular events, including all-cause death, cardiovascular death, recurrent myocardial infarction, hospitalization for heart failure, stent restenosis or thrombosis, severe bleeding, and aging-related serious adverse events.
Measured: Baseline through 24 months of follow-up
Secondary outcomes (6)
All-cause mortality
Death from any cause during follow-up.
Measured: Baseline through 24 months
Cardiovascular mortality
Death attributable to cardiovascular causes, including sudden cardiac death, heart failure, or cardiogenic shock.
Measured: Baseline through 24 months
Hospitalization for heart failure
Hospital admission due to worsening heart failure requiring intravenous diuretics, inotropic agents, or vasoactive therapy.
Measured: Baseline through 24 months
Recurrent myocardial infarction
New acute myocardial infarction occurring during follow-up according to standard diagnostic criteria.
Measured: Baseline through 24 months
Aging-related serious adverse events
Aging-related adverse outcomes, including cognitive decline, frailty-related fracture after low-energy falls, or loss of activities of daily living.
Measured: Baseline through 24 months
Prognostic performance of the aging-related risk prediction model
Predictive performance of the prognostic model integrating clinical characteristics, aging assessments, and aging-related biomarkers, evaluated using discrimination and calibration metrics.
Measured: At completion of the 24-month follow-up
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Jul 2026
- Study start1 Aug 2026 (estimated)
- Primary completion1 Aug 2030 (estimated)
- Study completion1 Sep 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Acute Myocardial Infarction (AMI)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 600 participants (estimated)
Sponsor and investigators
- Lead sponsor
- The Affiliated Hospital of Hangzhou Normal University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07705997
- Sponsor's protocol ID
- 2026（E2）-KS- 098
- Status last verified
- Jul 2026
- First submitted
- 10 Jul 2026
- Last updated
- 15 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 15 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Single-Center, Prospective, Observational Registry Cohort Study to Investigate Aging-Related Biomarkers, Prognosis, and Risk Prediction in Patients With Acute Myocardial Infarction
- ClinicalTrials.gov ID
- NCT07705997
- Acronym / sponsor ID
- 2026（E2）-KS- 098
- Conditions
- Acute Myocardial Infarction (AMI)
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 600 participants (estimated)
- Lead sponsor
- The Affiliated Hospital of Hangzhou Normal UniversityUniversity, hospital or other
- Study start
- 1 Aug 2026 (estimated)
- Primary completion
- 1 Aug 2030 (estimated)
- Study completion
- 1 Sep 2030 (estimated)
- First posted
- 15 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a single-center, prospective, observational cohort study designed to investigate the association between aging-related characteristics and long-term outcomes in patients with acute myocardial infarction (AMI). Approximately 588 eligible participants will be consecutively enrolled and followed for at least 24 months. Clinical data, aging assessments, laboratory examinations, cardiac imaging, and blood samples will be collected to establish a clinical database and biobank. The study aims to identify aging-related prognostic biomarkers, develop a risk prediction model integrating clinical and aging-related indicators, and improve risk stratification and individualized management for patients with AMI.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Patients With Acute Myocardial Infarction and Aging Characteristics | – | –Patients with acute myocardial infarction (AMI) and aging characteristics who meet the eligibility criteria will be consecutively enrolled in this prospective observational cohort. Participants will undergo comprehensive clinical evaluation, aging assessment, laboratory testing, cardiac imaging, biospecimen collection, and standardized follow-up for at least 24 months to investigate aging-related biomarkers, clinical outcomes, and prognostic risk prediction. |
Who may qualify
- Ages
- 60 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The study population includes consecutively enrolled patients with acute myocardial infarction (AMI) and aging characteristics at a single center. Eligible participants will undergo standardized clinical assessment, aging evaluation, biospecimen collection, and prospective follow-up to investigate aging-related biomarkers and long-term clinical outcomes.
Key inclusion criteria (1 listed)
- 1. Age ≥ 60 years old and meet the above comprehensive aging assessment criteria (i.e., combined with at least one clinical phenotype of aging and abnormal blood aging markers on the basis of advanced age); 2. Acute myocardial infarction occurs for ≥ 3 months; 3. Meet the diagnostic criteria for AMI in accordance with the Fourth Edition General Definition of Myocardial Infarction; 4. The patient or their legal representative signs an informed consent form.
Key exclusion criteria (1 listed)
- 1. Newly diagnosed acute myocardial infarction, angina pectoris, stroke or transient ischemic attack within the past 3 months; 2. Serious life-threatening diseases (such as advanced malignant tumors, end-stage kidney disease/liver disease, severe infections) with an estimated lifespan of less than 1 year; 3. Severe cognitive impairment, mental illness, inability to cooperate in completing follow-up, aging assessment, and related examinations; 4. Unable to complete assessment items such as grip strength, walking speed, and 6-minute walk test due to non cardiac reasons such as physical disabilities and severe bone and joint diseases; 5. Failed to sign the informed consent form.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Major adverse cardiovascular events (MACE)
Time frame: Baseline through 24 months of follow-up
The occurrence of major adverse cardiovascular events, including all-cause death, cardiovascular death, recurrent myocardial infarction, hospitalization for heart failure, stent restenosis or thrombosis, severe bleeding, and aging-related serious adverse events.
6 secondary outcomes
All-cause mortality
Time frame: Baseline through 24 months
Cardiovascular mortality
Time frame: Baseline through 24 months
Hospitalization for heart failure
Time frame: Baseline through 24 months
Recurrent myocardial infarction
Time frame: Baseline through 24 months
Aging-related serious adverse events
Time frame: Baseline through 24 months
Prognostic performance of the aging-related risk prediction model
Time frame: At completion of the 24-month follow-up
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Jul 2026.
Related trials for Acute Myocardial Infarction (AMI)
Not yet recruitingObservational study
Elicit Drugs in Myocardial Infarction
Young Patients With Acute Myocardial Infarction
Recruiting
CT Stress Myocardial Perfusion, Fractional Flow Reserve and Angiography in Patients With Stable Chest Pain Syndromes
Coronary Artery Disease, Chest Syndrome
RecruitingPhase 4
Early Single Antiplatelet Therapy After IVUS-Guided PCI in Acute Coronary Syndrome
Acute Coronary Syndromes, STEMI
Recruiting
Heart@Home Safety and Efficacy of Hospital-at-Home Care Versus Standard Hospitalization in Cardiac Patients
Myocardial Infarction, Myocarditis Acute
Enrolling by invitationPhase 3
Selatogrel Outcome Study in Suspected Acute Myocardial Infarction
Acute Myocardial Infarction
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Acute Myocardial Infarction (AMI), run by The Affiliated Hospital of Hangzhou Normal University at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 15 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Mingwei W Wang, PhD (18758871517 ext. not, wmw990556@163.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Major adverse cardiovascular events (MACE) (time frame: Baseline through 24 months of follow-up). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Jul 2026.